N-[4-(6-tert-butyl-1H-benzimidazol-2-yl)butyl]-N-[[(1R,3S)-3-[4-(cyclopropylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl]methyl]methanesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-[4-(6-tert-butyl-1H-benzimidazol-2-yl)butyl]-N-[[(1R,3S)-3-[4-(cyclopropylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentyl]methyl]methanesulfonamide
• 化学式: C₃₁H₄₃N₇O₂S
• 分子量: 577.8
• InChiKey: UUWRPRGVKWKRBO-QPPBQGQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA
  申请人：Epizyme, Inc.

  公开号：US20200113923A1

  公开（公告）日：2020-04-16

  The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
• [EN] DOT1 L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA<br/>[FR] INHIBITEURS DE DOT1 L À UTILISER DANS LE TRAITEMENT DE LA LEUCÉMIE
  申请人：EPIZYME INC

  公开号：WO2014100662A1

  公开（公告）日：2014-06-26

  The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT 1 -mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.